Autism spectrum disorders are prevalent among patients with dystrophinopathies.
Haruo FujinoToshio SaitoTsuyoshi MatsumuraSaki ShibataYuko IwataHarutoshi FujimuraOsamu ImuraPublished in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2018)
Recent studies have reported a higher prevalence of autism spectrum disorders among patients with dystrophinopathies. The aim of this study was to investigate the prevalence of autism spectrum disorder (ASD) among those with dystrophinopathies. The possible role of dystrophin isoforms in patients was also explored. Fifty-six patients recruited from Toneyama National Hospital were included in this study (mean age = 12.9 years, SD = 5.2 years). Autistic symptoms were evaluated using the Pervasive Developmental Disorders/Autism Spectrum Disorders Rating Scale (PARS), a clinician rating scale. Eleven patients (19.6%; 95% confidence interval 10.2-32.4) met the criteria for ASD based on their PARS scores. Patients were separated into two groups based on the cumulative loss of dystrophin isoforms predicted from the mutation location. The prevalence of ASD was examined between these groups. Infantile and current autistic symptoms did not differ between the groups, except on one subscale of the PARS. This study revealed that there was a high prevalence of ASD in patients with dystrophinopathies.
Keyphrases
- autism spectrum disorder
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- intellectual disability
- prognostic factors
- attention deficit hyperactivity disorder
- peritoneal dialysis
- healthcare
- emergency department
- physical activity
- patient reported outcomes
- sleep quality
- quality improvement